<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04018950</url>
  </required_header>
  <id_info>
    <org_study_id>CS2514-2018-0002</org_study_id>
    <nct_id>NCT04018950</nct_id>
  </id_info>
  <brief_title>Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects</brief_title>
  <official_title>Single Period, Open Label, Phase 1 Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entasis Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Entasis Therapeutics</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to determine the routes and rates of excretion of radio label&#xD;
      arising from 14C-ETX2514 and to characterize metabolites of ETX2514 arising from 14C-ETX2514&#xD;
      administered intravenously in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 21, 2019</start_date>
  <completion_date type="Actual">July 26, 2019</completion_date>
  <primary_completion_date type="Actual">July 26, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative urinary recovery of total radioactivity</measure>
    <time_frame>-12-0 hours (pre-dose), and at 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the intravenous (IV) dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative fecal recovery of total radioactivity</measure>
    <time_frame>-12-0 hours (pre-dose), and at 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the IV dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mass balance as a sum of the percent of total radioactivity recovered in urine and feces</measure>
    <time_frame>urine: -12-0 hours (pre-dose), and at 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the IV dose; feces: -12-0 hours (pre-dose), and at 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the IV dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiles in plasma</measure>
    <time_frame>pre-dose (-30 minutes) and at 1, 2 (± 2 minutes), 3 (just prior to shutting off infusion), 4, 6, 8, 10, 12 (± 5 minutes), 18, 24, 36, 48, 72, 96, 120, 144, and 168 hours (± 10 minutes) after the initiation of the IV dose or early termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiles in urine samples</measure>
    <time_frame>-12-0 hours (pre-dose) and over the following collection periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120,120-144, and 144-168 hours after the initiation of the IV dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite profiles in fecal samples</measure>
    <time_frame>-12-0 hours (pre-dose) and over the following collection periods: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the IV dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any treatment-emergent adverse event</measure>
    <time_frame>up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any clinically significant clinical laboratory evaluation</measure>
    <time_frame>up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any clinically significant vital sign measurement</measure>
    <time_frame>up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any clinically significant electrocardiogram finding</measure>
    <time_frame>up to Day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with any clinically significant physical examination finding</measure>
    <time_frame>up to Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Acinetobacter Baumannii-calcoaceticus Complex Infections</condition>
  <arm_group>
    <arm_group_label>ETX2514 and 14C-ETX2514</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravenous infusion of 1 gram non-labeled ETX2514 and 1 microCurie (µCi) of 14C-ETX2514 in normal saline, administered as a 3-hour infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ETX2514</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>ETX2514 and 14C-ETX2514</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C-ETX2514</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>ETX2514 and 14C-ETX2514</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male participants, between 18 and 55 years of age (inclusive) at the time of&#xD;
             Screening&#xD;
&#xD;
          -  Body mass index (BMI) ≥ 18.0 kilograms per meters squared (kg/m^2) and ≤ 32.0 kg/m^2&#xD;
             at Screening and weight between 55.0 and 100.0 kg (both inclusive) at Screening and&#xD;
             Day -1&#xD;
&#xD;
          -  Able to understand and willing to sign the Informed Consent Form (ICF), and willing&#xD;
             and able to comply with the study restrictions and investigative site rules for&#xD;
             participants&#xD;
&#xD;
          -  Judged to be in good health in the opinion of the Investigator on the basis of a&#xD;
             medical evaluation (including a physical examination, medical history,&#xD;
             electrocardiograms vital signs, and the results of biochemistry and hematology tests&#xD;
             and urinalysis carried out at Screening, Day -1 and pre-dose on Day 1) that does not&#xD;
             reveal any clinically significant abnormality, which evaluation will consider&#xD;
             acceptable the presence of a stable condition (e.g., hypertension, hyperlipidemia,&#xD;
             diabetes mellitus, hypothyroidism) that may be under medical control (i.e., adequate&#xD;
             and stable treatment) having no clinical consequences of the condition that, in the&#xD;
             judgment of the Investigator, would increase risk to the participant's health by&#xD;
             participating in this study or would increase risk of not achieving the study&#xD;
             objectives&#xD;
&#xD;
          -  Participants with normal renal function as evidenced by creatinine clearance (CLcr)&#xD;
             estimated by Cockcroft Gault formula&#xD;
&#xD;
          -  Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Male participants with female partners of childbearing potential may be enrolled if&#xD;
             they are:&#xD;
&#xD;
               1. documented to be surgically sterile (vasectomy); or&#xD;
&#xD;
               2. using two adequate forms of highly effective contraception (together with the&#xD;
                  female partner), out of which one will be a physical barrier (i.e., condom&#xD;
                  combined with partner oral contraceptive, implant, injectable, or indwelling&#xD;
                  intrauterine device), for 90 days after the study drug administration&#xD;
&#xD;
          -  Must agree not to donate sperm from the Screening period through 90 days after the&#xD;
             last dose&#xD;
&#xD;
          -  Has sufficiently good venous access in both arms to confidently enable intravenous&#xD;
             administration of study drug in one arm and serial blood sampling from the other arm&#xD;
&#xD;
          -  Content of 14C in one or both (at Investigator's discretion) of urine and blood (or&#xD;
             plasma) samples obtained at Screening does not significantly exceed the general&#xD;
             environmental background 14C level&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of oncologic, cardiovascular, pulmonary, hepatic, renal,&#xD;
             hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological,&#xD;
             psychiatric or other disease or condition that in the Investigator's judgment poses a&#xD;
             significant risk to the safety of the volunteer or the achievement of study objectives&#xD;
&#xD;
          -  Clinically significant abnormal medical history, abnormal findings on physical&#xD;
             examination, vital signs, electrocardiograms, or laboratory tests at Screening, Day -1&#xD;
             or pre-dose on Day 1 that the Investigator judges may put at risk achieving the&#xD;
             objectives of the trial or protecting the safety of the volunteer&#xD;
&#xD;
          -  History of cancer judged not to be in full remission for at least 5 years (except&#xD;
             basal cell skin cancer or squamous cell skin cancer with history of curative treatment&#xD;
             and no recurrence for at least 1 year prior to screening), as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Any acute illness including clinically significant infection within 30 days prior to&#xD;
             Screening&#xD;
&#xD;
          -  Acute illness within 14 days prior to study drug administration unless mild in&#xD;
             severity and enrollment is approved by both Investigator and Sponsor's medical&#xD;
             representative&#xD;
&#xD;
          -  Presence of active infection requiring antibiotic treatment&#xD;
&#xD;
          -  History of multiple and/or severe allergies to drugs or foods or a history of&#xD;
             anaphylactic reaction&#xD;
&#xD;
          -  Uncontrolled hyperuricemia (serum uric acid &gt; upper limit of normal [ULN])&#xD;
&#xD;
          -  Concomitant use of medications known to affect the elimination of serum creatinine&#xD;
             (e.g., trimethoprim or cimetidine) or to compete for renal tubular secretion (e.g.,&#xD;
             probenecid) within 60 days prior to study drug administration&#xD;
&#xD;
          -  Documented congenital or acquired long QT syndrome&#xD;
&#xD;
          -  Corrected QT interval (QTc) using Fridericia correction (QTcF) at Screening, Day -1,&#xD;
             or pre-dose (Day 1) &gt; 450 milliseconds&#xD;
&#xD;
          -  Family history of long QT syndrome or of unexplained sudden death in a first-degree&#xD;
             relative under age 50&#xD;
&#xD;
          -  Uncontrolled treated/untreated hypertension (defined as a mean of 3 repeated&#xD;
             measurements with approximately 5 minutes of resting time between each measurement for&#xD;
             systolic blood pressure [SBP] ≥ 140 millimeters of mercury (mmHg) and/or diastolic&#xD;
             blood pressure [DBP] ≥ 100 mmHg&#xD;
&#xD;
          -  Current presence of clinically significant hypotension (systolic blood pressure [SBP]&#xD;
             &lt; 90 mmHg and/or diastolic blood pressure [DBP] &lt; 50 mmHg)&#xD;
&#xD;
          -  Positive alcohol breath test or urine drug screen test at screening and/or Day -1&#xD;
&#xD;
          -  Recent history of incomplete bladder emptying with voiding or of awaking more than&#xD;
             once at night to void&#xD;
&#xD;
          -  Usual habit of less than one or more than three bowel movements per day&#xD;
&#xD;
          -  Positive testing for human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C&#xD;
&#xD;
          -  History or presence of alcohol or drug abuse within the 2 years prior to Screening&#xD;
&#xD;
          -  Excessive intake of alcohol, defined as an average daily intake of greater than three&#xD;
             units, or an average weekly intake of greater than 21 units (one unit is equivalent to&#xD;
             1 can or bottle [12 ounces (oz)] of beer, or 1 measure [1.5 oz] of spirits, or 1 glass&#xD;
             [5 oz] of wine) in the last 6 months prior to Screening&#xD;
&#xD;
          -  Use of any prescription (including proton pump inhibitors [PPIs] and diuretics) or&#xD;
             non-prescription drugs, including over-the-counter medication, health supplements,&#xD;
             non-routine vitamins and herbal products such as St. John's Wort, within 2 weeks prior&#xD;
             to study drug administration unless discussed and agreed with the Sponsor's medical&#xD;
             representative in writing. Use of the following may be allowed within the 2 weeks&#xD;
             prior to study drug administration:&#xD;
&#xD;
               1. Topically applied medication (eye and/or nose drops/spray or&#xD;
                  creams/ointment/lotion applied to skin);&#xD;
&#xD;
               2. Occasional use of metoclopramide or ibuprofen;&#xD;
&#xD;
               3. Use of multivitamins, vitamin C (allowed up to 7 days prior to study drug&#xD;
                  administration), and acetaminophen (allowed up to 3 days prior to study drug&#xD;
                  administration).&#xD;
&#xD;
          -  Use of caffeine or other xanthine containing products (coffee, black tea, green tea,&#xD;
             decaffeinated coffee, decaffeinated tea, colas, kola, chocolate, cacao, guarana,&#xD;
             guayusa, yerba mate), Seville oranges (sour/bitter or &quot;marmalade&quot;), grapefruit or&#xD;
             grapefruit juice within 48 hours prior to study drug dosing&#xD;
&#xD;
          -  History or evidence of difficulty with venous access or adverse symptoms in donating&#xD;
             blood&#xD;
&#xD;
          -  Participation in another investigational drug trial within 30 days prior to study drug&#xD;
             administration (or 5 times the half-life of any drug used in the prior study,&#xD;
             whichever is longer) or exposure to more than three new investigational agents within&#xD;
             12 months prior to study drug administration&#xD;
&#xD;
          -  Exposure to radiation for therapeutic or diagnostic reasons (except dental X-rays and&#xD;
             plain X-rays of thorax and bony skeleton) within the last 12 months prior to dosing of&#xD;
             the investigational drug, or an occupationally exposed worker&#xD;
&#xD;
          -  Participation in another clinical trial in which a [14C]-labeled drug was administered&#xD;
             within the year prior to Day -1&#xD;
&#xD;
          -  Donation or loss of more than 450 milliliters blood during the 3 months before the&#xD;
             start of Screening&#xD;
&#xD;
          -  Unwilling to avoid strenuous or unaccustomed activity, sunbathing, or contact sports&#xD;
             within 96 hours (4 days) prior to entry in the clinic research center&#xD;
&#xD;
          -  History of seizures, head injury with loss of consciousness or meningitis&#xD;
&#xD;
          -  History of bleeding disorders&#xD;
&#xD;
          -  Surgery within the past 3 months prior to Screening determined by the investigator to&#xD;
             be clinically relevant&#xD;
&#xD;
          -  Participants who have any of the following abnormalities on laboratory values at&#xD;
             Screening or on Day -1 including:&#xD;
&#xD;
               1. White blood cell count &lt; 3000/millimeters cubed (mm^3), hemoglobin &lt; 11 grams per&#xD;
                  deciliter (g/dL);&#xD;
&#xD;
               2. Absolute neutrophil count &lt; 1200/mm^3, platelet count &lt; 120,000/mm^3;&#xD;
&#xD;
               3. Serum Alkaline phosphatase (AP) &gt; 1.5x ULN;&#xD;
&#xD;
               4. Serum transaminase (alanine aminotransferase [ALT] or aspartate aminotransferase&#xD;
                  [AST]) &gt; ULN&#xD;
&#xD;
          -  Any other reason, condition or prior therapy, which, in the opinion of the Principal&#xD;
             Investigator, would make the participant unsuitable for this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pharmaron Clinical Pharmacology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acinetobacter baumannii-calcoaceticus</keyword>
  <keyword>complex infections</keyword>
  <keyword>ETX2514</keyword>
  <keyword>excretion</keyword>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

